Cancer Family
Carcinoma
CI-CAN-00000114Explore in graph →
7,369 active trials118 approved drugs1,149 evidence items
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000114Explore in graph →
Clinical trials
25,729 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (3,405)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT03552796 | sEphB4-HSA in Treating Participants With BCG-Unresponsive or Refractory Bladder Cancer | withdrawn | Phase 1 | 0 | University of Southern CaliforniaOTHER | 1 | Jun 26, 2023 | clinicaltrials |
| NCT05603299 | Establishing Clinical Utility Evidence to Support Coverage and Reimbursement for Venn Biosciences' Dawn Test | withdrawn | N/A | 0 | Qure Healthcare, LLCINDUSTRY | 0 | Jun 15, 2023 | clinicaltrials |
| NCT05411679 | EP0057 in Combination With Olaparib in Relapsed Advanced Gastric Cancer and Small Cell Lung Cancer | withdrawn | Phase 2 | 0 | Ellipses PharmaINDUSTRY | 3 | Jun 12, 2023 | clinicaltrials |
| NCT04699968 | A Trial of SHR-1701 With or Without Famitinib in Patients With Advanced or Metastatic NSCLC | withdrawn | Phase 2 | 0 | Jiangsu HengRui Medicine Co., Ltd.INDUSTRY | 0 | Jun 7, 2023 | clinicaltrials |
| NCT05582031 | Regorafenib With Tislelizumab in Patients With Selected Mismatch Repair-Proficient/Microsatellite Stable Cancers(REFIT-MSS) | withdrawn | Phase 2 | 0 | Translational Research in OncologyOTHER | 0 | Jun 7, 2023 | clinicaltrials |
| NCT04625699 | Study of Durvalumab + Tremelimumab in NSCLC Patients After Adjuvant Treatment | withdrawn | Phase 2 | 0 | Catherine ShuOTHER | 0 | Jun 6, 2023 | clinicaltrials |
| NCT04987996 | GR-MD-02 + Pembrolizumab Versus Pembrolizumab Monotherapy in Melanoma and Squamous Cell Head and Neck Cancer Patients | withdrawn | Phase 2 | 0 | Providence Health & ServicesOTHER | 1 | Jun 6, 2023 | clinicaltrials |
| NCT05886257 | Candonilimab Plus Bevacizumab for Patients With Advanced HCC Who Progressed on A+T | withdrawn | Phase 2 | 0 | Shi MingOTHER | 1 | Jun 2, 2023 | clinicaltrials |
| NCT02344810 | C-Met Inhibitor AMG 337, Oxaliplatin, Leucovorin Calcium, and Fluorouracil in Treating Patients With Advanced Stomach or Esophageal Cancer | withdrawn | Phase 1 / Phase 2 | 0 | Eastern Cooperative Oncology GroupNETWORK | 1 | May 25, 2023 | clinicaltrials |
| NCT02607423 | Fludeoxyglucose F-18 PET/CT in Predicting Response to Chemotherapy in Patients With Stage IIIA Non-small Cell Lung Cancer That Can Be Removed by Surgery | withdrawn | Phase 2 | 0 | ECOG-ACRIN Cancer Research GroupNETWORK | 1 | May 25, 2023 | clinicaltrials |
| NCT04190433 | Autophagy Activation for the Alleviation of Cardiomyopathy Symptoms After Anthracycline Treatment, ATACAR Trial | withdrawn | Phase 2 | 0 | Mayo ClinicOTHER | 0 | May 24, 2023 | clinicaltrials |
| NCT05743777 | PembROlizumab With or Without Microbial EcOsystem ThErapeutic 4 (MET4) in Advanced Head and Neck Squamous Cell Carcinoma(PROMOTE-HN) | withdrawn | Phase 2 | 0 | Canadian Cancer Trials GroupNETWORK | 0 | May 18, 2023 | clinicaltrials |
| NCT05774886 | Implantable Microdevice for TNBC - Pilot Study | withdrawn | Phase 1 | 0 | Dana-Farber Cancer InstituteOTHER | 0 | May 18, 2023 | clinicaltrials |
| NCT04603365 | Pamiparib and Temozolomide for the Treatment of Hereditary Leiomyomatosis and Renal Cell Cancer | withdrawn | Phase 2 | 0 | Jonsson Comprehensive Cancer CenterOTHER | 0 | May 17, 2023 | clinicaltrials |
| NCT05736952 | Oral Topotecan Combined With Anlotinib in Patients With Platinum-resistant Recurrent Ovarian Cancer | withdrawn | Phase 2 | 0 | Xinhua Hospital, Shanghai Jiao Tong University School of MedicineOTHER | 1 | May 11, 2023 | clinicaltrials |
| NCT05368506 | ZN-c3 for the Treatment of Metastatic Triple-Negative Breast Cancer and Advanced Ovarian Cancer | withdrawn | Early Phase 1 | 0 | OHSU Knight Cancer InstituteOTHER | 0 | May 6, 2023 | clinicaltrials |
| NCT02174575 | Anesthetic Agents and Acute Kidney Injury After Liver Resection Surgery | withdrawn | Phase 4 | 0 | Tokyo Medical and Dental UniversityOTHER | 1 | May 3, 2023 | clinicaltrials |
| NCT04879589 | Phase 1 Study of ATRS-2002 in Healthy Male Adults | withdrawn | Phase 1 | 0 | Syneos HealthOTHER | 0 | Apr 28, 2023 | clinicaltrials |
| NCT01971489 | Buparlisib, Gemcitabine Hydrochloride, and Cisplatin in Treating Patients With Advanced Solid Tumors | withdrawn | Phase 1 | 0 | Roswell Park Cancer InstituteOTHER | 1 | Apr 27, 2023 | clinicaltrials |
| NCT03632369 | Hyperpolarized Noble Gas MRI Detection of Radiation-Induced Lung Injury | withdrawn | — | 0 | Thunder Bay Regional Health Research InstituteOTHER | 0 | Apr 25, 2023 | clinicaltrials |
| NCT05220748 | RM-1995 Photoimmunotherapy, as Monotherapy or Combined With Pembrolizumab, in Patients With Advanced CuSCC and HNSCC | withdrawn | Phase 1 | 0 | Rakuten Medical, Inc.INDUSTRY | 0 | Apr 19, 2023 | clinicaltrials |
| NCT05107427 | Study of MRx0518 and Avelumab in Patients With Urothelial Carcinoma(AVENU) | withdrawn | Phase 2 | 0 | 4D pharma plcINDUSTRY | 1 | Apr 18, 2023 | clinicaltrials |
| NCT05496192 | A Study of Nivolumab Intravenous (IV) to Subcutaneous (SC) Switch in Adjuvant Melanoma and Bladder Cancer | withdrawn | Phase 2 | 0 | Bristol-Myers SquibbINDUSTRY | 2 | Apr 14, 2023 | clinicaltrials |
| NCT04852367 | PanDox: Targeted Doxorubicin in Pancreatic Tumours(PanDox) | withdrawn | Phase 1 | 0 | University of OxfordOTHER | 1 | Apr 12, 2023 | clinicaltrials |
| NCT01332279 | Everolimus, Erlotinib Hydrochloride, and Radiation Therapy in Treating Patients With Recurrent Head and Neck Cancer Previously Treated With Radiation Therapy | withdrawn | Phase 1 | 0 | Fox Chase Cancer CenterOTHER | 1 | Apr 4, 2023 | clinicaltrials |
| NCT05157451 | Y-90 Versus SBRT for Inoperable HCC | withdrawn | Phase 2 | 0 | OHSU Knight Cancer InstituteOTHER | 0 | Mar 23, 2023 | clinicaltrials |
| NCT05212922 | A Study to Evaluate YH001 in Combination With Toripalimab in Subjects With Advanced NSCLC and HCC(YH001) | withdrawn | Phase 2 | 0 | Eucure (Beijing) Biopharma Co., LtdINDUSTRY | 5 | Mar 20, 2023 | clinicaltrials |
| NCT05693090 | Tipifarnib and Osimertinib in EGFR-mutated Non-Small Cell Lung Cancer | withdrawn | Phase 1 | 0 | Kura Oncology, Inc.INDUSTRY | 1 | Mar 6, 2023 | clinicaltrials |
| NCT04650490 | SRS Timing With Immune Checkpoint Inhibition in Patients With Untreated Brain Metastases From Non-small Cell Lung Cancer(STICk-IM-NSCLC) | withdrawn | Phase 2 | 0 | Duke UniversityOTHER | 1 | Mar 2, 2023 | clinicaltrials |
| NCT02899325 | FDGal PET/CT to Detect Hepatocellular Carcinoma | withdrawn | — | 0 | British Columbia Cancer AgencyOTHER | 1 | Feb 21, 2023 | clinicaltrials |
| NCT04965714 | Nivolumab and ADI-PEG 20 Before Surgery for the Treatment of Resectable Liver Cancer | withdrawn | Phase 2 | 0 | M.D. Anderson Cancer CenterOTHER | 1 | Feb 16, 2023 | clinicaltrials |
| NCT05592197 | Safety and Efficacy of Radiation Plus TACE and Lenvatinib in Advanced HCC With PVTT | withdrawn | N/A | 0 | Sun Yat-sen UniversityOTHER | 1 | Feb 16, 2023 | clinicaltrials |
| NCT05533320 | Portable Scalp Cooling System for the Improvement of Chemotherapy-Induced Hair Loss in Patients With Metastatic Breast Cancer | withdrawn | N/A | 0 | City of Hope Medical CenterOTHER | 0 | Feb 2, 2023 | clinicaltrials |
| NCT03982173 | Basket Trial for Combination Therapy With Durvalumab (Anti-PDL1) (MEDI4736) and Tremelimumab (Anti-CTLA4) in Patients With Metastatic Solid Tumors(MATILDA) | withdrawn | Phase 2 | 0 | Gustave Roussy, Cancer Campus, Grand ParisOTHER | 0 | Jan 26, 2023 | clinicaltrials |
| NCT05628545 | Adoptive Treatment of Advanced Hepatocellular Carcinoma With Allogeneic γδ-T Cells | withdrawn | Phase 1 / Phase 2 | 0 | Guangdong GD Kongming Biotech LLCINDUSTRY | 1 | Jan 18, 2023 | clinicaltrials |
| NCT03666819 | Carbon Dioxide Fractional Laser in Treating Participants With Stage 0-III Hormone Receptor-Positive Breast Cancer With Vulvovaginal Atrophy | withdrawn | Phase 2 | 0 | Mayo ClinicOTHER | 0 | Jan 6, 2023 | clinicaltrials |
| NCT04249167 | Cryoablation, Atezolizumab/Nab-paclitaxel for Locally Advanced or Metastatic Triple Negative Breast Cancer | withdrawn | Early Phase 1 | 0 | Mayo ClinicOTHER | 0 | Jan 6, 2023 | clinicaltrials |
| NCT05512767 | A Pneumatic Compression Device for the Treatment of Lymphedema in Patients With Stage II-IV Head and Neck Cancer After Chemoradiation | withdrawn | N/A | 0 | Mayo ClinicOTHER | 0 | Jan 6, 2023 | clinicaltrials |
| NCT05472220 | Alpelisib in Combination With Carboplatin in Patients With Solid Tumors and HPV-Positive Squamous Cell Carcinoma | withdrawn | Phase 1 | 0 | Pamela MunsterOTHER | 0 | Dec 27, 2022 | clinicaltrials |
| NCT04941365 | Quantifying Systemic Immunosuppression to Personalize Cancer Therapy(SERPENTINE) | withdrawn | N/A | 0 | Institut du Cancer de Montpellier - Val d'AurelleOTHER | 0 | Dec 22, 2022 | clinicaltrials |
| NCT04291950 | Epigenetics of TNBC in Overweight and Obese Hispanic & Non-Hispanic White Women | withdrawn | — | 0 | University of ArizonaOTHER | 1 | Dec 20, 2022 | clinicaltrials |
| NCT05393635 | ITIL-168 in Advanced Solid Tumors(DELTA-2) | withdrawn | Phase 1 | 0 | Instil BioINDUSTRY | 0 | Dec 20, 2022 | clinicaltrials |
| NCT05062174 | Breast Cancer BRCA1 Carriers: a Pilot Study | withdrawn | — | 0 | Indiana UniversityOTHER | 1 | Dec 15, 2022 | clinicaltrials |
| NCT04178642 | The Impact on Hepatic Recurrence After Adjuvant Chemotherapy With Intraarterial Infusion of Idarubicin-Lipiodol(LIDA-ADJ) | withdrawn | Phase 2 | 0 | University Hospital, MontpellierOTHER | 1 | Dec 14, 2022 | clinicaltrials |
| NCT05327738 | Yttrium Y 90 Glass Microspheres, Atezolizumab, and Cabozantinib for the Treatment of Unresectable or Locally Advanced Hepatocellular Carcinoma | withdrawn | Phase 2 | 0 | OHSU Knight Cancer InstituteOTHER | 0 | Dec 14, 2022 | clinicaltrials |
| NCT05233696 | Radiotherapy in Combo With Chemo and Immunotherapy in Patients With PD-L1 Positive Metastatic TNBC | withdrawn | Phase 2 | 0 | University of Colorado, DenverOTHER | 1 | Dec 6, 2022 | clinicaltrials |
| NCT05325164 | Methadone for 'Adenocarcinopathic' Pain Treatment(METHADOPT) | withdrawn | Phase 3 | 0 | Ottawa Hospital Research InstituteOTHER | 0 | Dec 5, 2022 | clinicaltrials |
| NCT05481775 | Evaluating Efficacy and Safety of Anlotinib Combined With Concurrent Chemoradiotherapy Followed by Consolidation Immunotherapy for Locally Advanced Non-small Cell Lung Cancer | withdrawn | Phase 2 | 0 | Sun Yat-sen UniversityOTHER | 1 | Nov 21, 2022 | clinicaltrials |
Data updated 23 days agoSource updated Jun 26, 2023source: clinicaltrials